<DOC>
	<DOCNO>NCT01475136</DOCNO>
	<brief_summary>This study explore liver impairment effect blood level LY2140023 ( prodrug ) active metabolite LY404039 .</brief_summary>
	<brief_title>A Study LY2140023 Hepatic Impaired Participants</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Male participant agree use reliable method birth control study 3 month follow last dose LY2140023 Female participant childbearing potential test negative pregnancy screen agree use reliable method birth control duration study least 3 month last dose LY2140023 Female participant postmenopausal . Postmenopausal define menses least 1 year , plasma follicle stimulate hormone ( FSH ) value great 40 IU/L , unless participant take hormone replacement therapy Have body mass index ( BMI ) 19 40 kg/m^2 , inclusive time screen Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator Have sit blood pressure heart rate compatible disease state , determine investigator Have venous access sufficient allow blood sample per protocol Are reliable willing make available duration study willing follow study procedure Have give write informed consent approve Lilly ethical review board ( ERB ) govern site Control participants normal hepatic function , determine medical history physical examination Hepatically impair participant stable hepatic impairment ( example , alcoholic , posthepatitis , biliary cirrhosis , cryptogenic ) classify ChildPugh class A , B , C ( mild , moderate , severe impairment ) consider acceptable participation study investigator Are currently enrol , complete discontinue within last 90 day last dosing investigational product ( investigational product use study ) ; concurrently enrol type medical research judge scientifically medically compatible study Have know allergy LY2140023 , LY404039 , related compound , component formulation Have previously discontinue receive least 1 dose LY2140023 complete study study investigate LY2140023 LY404039 Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study Have history presence cardiovascular , respiratory , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption ( except cholecystectomy ) , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Have evidence significant active neuropsychiatric disease ( example , manic depressive illness , schizophrenia , depression ) Participants answer 'yes ' either Question 4 ( Active Suicidal Ideation Some Intent Act , Without Specific Plan ) Question 5 ( Active Suicidal Ideation Specific Plan Intent ) `` Suicidal Ideation '' portion CSSRS , answer `` yes '' suiciderelated behavior ( actual attempt , interrupt attempt , abort attempt , preparatory act , behavior ) `` Suicidal Behavior '' portion Columbia Suicide Severity Rating Scale ( CSSRS ) ; ideation behavior occur within past 3 month Have increase risk seizure base history : One seizure ( except single simple febrile seizure [ lack focality last less 15 minute , associated central nervous system ( CNS ) infection severe metabolic disturbance ] child age 6 month 5 year ) Head trauma loss consciousness postconcussive syndrome within 1 year lifetime history head trauma persistent neurological deficit ( focal diffuse ) CNS infection , uncontrolled migraine transient ischemic attack ( TIA ) within 1 year ; stroke persistent neurological deficit ( focal diffuse ) , uncontrolled migraine define migraine attack produce headache last 72 hour often accompany associate symptom ( nausea , photophobia , phonophobia ) impair wellbeing disrupt social functioning . TIA define `` ministroke '' cause temporary disturbance blood supply area brain , result sudden , brief decrease brain function CNS infection persistent neurological deficit ( focal diffuse ) Brain surgery Electroencephalogram ( EEG ) paroxysmal ( epileptiform ) activity ( isolated spike wave , repetitive burst sharp wave , paroxysmal activity , frank seizure , spikewave complex , sharpslow wave complex , locally define ) Brain structural lesion , include developmental abnormality , determine examination image study ( include hydrocephalus unless treat shunt result neurological deficit ) Known substance dependence unless approve prescription medication opiate , know regular use drug abuse and/or show positive finding urinary drug screen Show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody Women pregnant intend get pregnant study within 3 month last dose investigational product Women breast feed lactate Have donate blood 500 mL within last 3 month prior screen Are organ transplant participant take immunosuppressant follow organ transplant Have show sign variceal bleed last 2 month prior screen ( except participant severe hepatic impairment , detailed exclusion criterion ) Show evidence irritable bowel syndrome chronic diarrhea Have average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) , participant unwilling stop alcohol consumption 96 hour predose 48 hour postdose ( 1 unit equal 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Have clinically significant abnormality neurological examination Participants judge prior dose suicidal risk investigator Participants unwilling refrain smoking midnight prior dose 6 hour postdose unable abide Clinical Research Unit ( CRU ) restriction Are total parenteral nutrition ( TPN ) Take oral anticoagulant therapeutic use Exhibit condition , , opinion investigator would preclude participation study Show evidence pruritus skin exfoliation Have eosinophil count &gt; 1.5 x 10^9/L Have electrolyte imbalance alert ( clinically significant change calcium magnesium , sodium ) Control Participants : Have medically significant history neurologic disease , cancer , cardiac , respiratory , metabolic , hepatic , renal , gastrointestinal ( except appendectomy ) , dermatological , venereal , hematological disorder disease Have creatinine clearance ( CrCl ) less 80 mL/min , calculate CockcroftGault equation Men : [ ( 140 age ) x ( weight kg ) ] / [ 72 x ( serum creatinine mg/100 mL ) ] [ ( 140 age ) x ( weight kg ) ] / [ 0.81 x ( serum creatinine Âµmol/L ) ] Women equation : ( x 0.85 ) Show evidence significant active neuropsychiatric disease opinion investigator Evidence hepatitis B and/or positive hepatitis B surface antigen ( HBsAg ) Show evidence hepatitis C and/or positive hepatitis C antibody Intend use overthecounter medication ( include herbal remedies/health supplement ) within 7 day prior dose , prescription medication ( hormone replacement therapy describe inclusion criterion 1 ) within 14 day prior dose Mild Hepatic Impaired Participants ( ChildPugh A ) : show evidence significant active disease responsible associate hepatic impairment platelet count le 50 x 10^9 cells/L unless consultation Lilly Clinical Pharmacologist ( CP ) , consider acceptable participation study Moderate Severe Hepatic Impaired Participants ( ChildPugh B C ) : Show evidence significant active disease responsible associate moderate severe hepatic impairment Have show sign spontaneous bacterial peritonitis within 6 month prior dose Have severe hyponatremia Show evidence significant active neuropsychiatric disease Have hepatic encephalopathy ( Grades 2 4 ) Have hemoglobin concentration &lt; 9.0 g/dL Show sign hepatocellular carcinoma Have surgical portosystemic shunt Have platelet count le 40 x 10^9 cells/L ( moderate impairment ) less 30 x 10^9 cells/L ( severe impairment ) , unless consultation Lilly CP , consider acceptable participation study Have show sign variceal bleed last 2 week prior screen ( severe hepatic impaired participant )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>